bimatoprost ophthalmic (T4032) / Thea Laboratories - LARVOL DELTA

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients (clinicaltrials.gov) - P3 | N=684 | Completed | Sponsor: Laboratoires Thea | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Glaucoma • Ophthalmology

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients (clinicaltrials.gov) - P3 | N=684 | Active, not recruiting | Sponsor: Laboratoires Thea | Recruiting ➔ Active, not recruiting | N=500 ➔ 684 | Trial completion date: Aug 2023 ➔ Mar 2024 | Trial primary completion date: Aug 2023 ➔ Mar 2024

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Laboratoires Thea | Not yet recruiting ➔ Completed

Trial completion

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Laboratoires Thea

New P1 trial

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients (clinicaltrials.gov) - P3 | N=500 | Recruiting | Sponsor: Laboratoires Thea | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Glaucoma • Ophthalmology

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients (clinicaltrials.gov) - P3 | N=500 | Not yet recruiting | Sponsor: Laboratoires Thea

New P3 trial • Glaucoma • Ophthalmology